MoonLake Immunotherapeutics — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MoonLake Immunotherapeutics filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($227.32M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($118.94M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($36.01M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($49.97M) | Feb 26, 2025 |
| FY2022 | Dec 31, 2021 | ($53.64M) | Mar 20, 2023 |
| FY2020 | Dec 31, 2020 | ($90.8K) | Dec 14, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($244.83M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($143.09M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($54.12M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($65.06M) | Feb 26, 2025 |
| FY2022 | Dec 31, 2021 | ($53.58M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($105.8K) | Feb 17, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.86M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $112.77M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $31.80M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $42.05M | Feb 26, 2025 |
| FY2022 | Dec 31, 2021 | $35.53M | Mar 20, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($196.01M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($116.59M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($42.78M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($55.89M) | Feb 26, 2025 |
| FY2022 | Dec 31, 2021 | ($35.18M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($316.7K) | Feb 17, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $520.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $284.0K | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $16.0K | Feb 26, 2025 |
| FY2022 | Dec 31, 2021 | $50.7K | Mar 20, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $424.43M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $477.93M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $526.54M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $76.84M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $9.68M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $116.63M | Feb 17, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.95M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $24.54M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $13.05M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $8.08M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $21.33M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $4.15M | Feb 17, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $304.48M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $446.83M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $495.68M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $48.90M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($11.65M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($2.52M) | Feb 17, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($462.91M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($235.59M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($116.66M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($80.65M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($53.64M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($2.52M) | Feb 17, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $334.52M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $180.43M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $451.17M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $39.51M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $8.04M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $1.34M | Feb 17, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 25, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2022 | Dec 31, 2021 | (6) | Mar 20, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2022 | Dec 31, 2021 | (6) | Mar 20, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Apr 5, 2022 | 52.70M | Feb 26, 2025 |